Stockscreener 앱 받기
1.031
6.27%
-0.069
전일 마감가:
$1.10
열려 있는:
$1.0651
하루 거래량:
8,418
Relative Volume:
0.05
시가총액:
$8.32M
수익:
$4.83M
순이익/손실:
$-2.99M
주가수익비율:
-2.1461
EPS:
-0.4804
순현금흐름:
$-2.83M
1주 성능:
-5.41%
1개월 성능:
-17.52%
6개월 성능:
+27.95%
1년 성능:
-36.36%
1일 변동 폭
$1.02
$1.0651
1주일 범위
$1.02
$1.1538
52주 변동 폭
$0.6765
$2.39
이뮤론 Stock (IMRN) Company Profile
Compare IMRN vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
1.031 | 8.56M | 4.83M | -2.99M | -2.83M | -0.4804 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
이뮤론 주식(IMRN)의 최신 뉴스
Immuron Limited Sponsored ADR Revenue Breakdown – MUN:ANWA - TradingView
Immuron Limited Sponsored ADR Revenue Breakdown – LSX:A2DTD8 - TradingView
Immuron Limited (NASDAQ: IMRN) grows FY26 revenue to A$7.7m - Stock Titan
Immuron FY26 SalesFour Consecutive Quarters of Growth over Prior Year - Sahm
BNY Mellon Lifts Substantial Holding in Immuron to 44.61% via ADR Program Deposits - Kalkine
Immuron (NASDAQ: IMRN) lifts FY26 Travelan sales 6% to AUD$7.7m - Stock Titan
BNY Mellon Boosts Immuron Stake to 44.61% Through ADR Share Deposits by July 2026 - Kalkine Media
Immuron (NASDAQ: IMRN) advances IMM-529 CDI drug with new partnering push - Stock Titan
Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy - GlobeNewswire Inc.
IMRNImmuron Limited ADR Revenue Breakdown - Finviz
A2DTD8 Forecast — Price Target — Prediction for 2027 - TradingView
ANWA Forecast — Price Target — Prediction for 2027 - TradingView
Immuron (NASDAQ: IMRN) now has 322.8M ordinary shares on issue - Stock Titan
Price to earnings forward of Immuron Limited Sponsored ADR – MUN:ANWA - TradingView
Immuron Limited Sponsored ADR Actuals & Estimates (NASDAQ:IMRN) - TradingView
Form 6K Immuron Ltd ADR For: 23 June By Investing.com - Investing.com South Africa
Form 6K Immuron Ltd ADR For: 23 June - Investing.com UK
Immuron (NASDAQ: IMRN) cancels 3.8M shares in small holder buy-back - Stock Titan
Immuron (NASDAQ: IMRN) reports expiry of 1.43M options and updated capital - Stock Titan
Which stocks have an unusual volume on Thursday? - ChartMill
Immuron (NASDAQ: IMRN) responds to ASX query on share price - Stock Titan
Wondering what's happening in today's after-hours session? - ChartMill
Immuron (IMRN) CCO reports 1.14M shares and 640K performance rights in Form 3 - Stock Titan
Number of shareholders of Immuron Limited Sponsored ADR – LSX:A2DTD8 - TradingView
Immuron (NASDAQ: IMRN) details TD portfolio growth and partnering push - Stock Titan
Immuron (IMRN) chairman discloses 1.67M share options - Stock Titan
Immuron (NASDAQ: IMRN) CEO schedules Emerging Growth Conference presentation - Stock Titan
Unusual VolumeStock ScreenerNews - Finviz
IMRN Stock Price, Quote & Chart | IMMURON LTD-SPON ADR (NASDAQ:IMRN) - ChartMill
Immuron Double Digit 3Q Sales Growth - Sahm
Top 10 at 11: Wall Street hits all-time highs but ASX opens lower as banks retreat - MSN
Immuron (NASDAQ: IMRN) lifts Travelan sales with strong Canada Q3 surge - Stock Titan
Immuron (NASDAQ: IMRN) offers cost-free sale facility for small shareholdings - Stock Titan
Operating cash flow per share of Immuron Limited Sponsored ADR – GETTEX:ANWA - TradingView
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target - Democrat and Chronicle
IMRN Earnings History & Surprises | EPS & Revenue Results | IMMURON LTD-SPON ADR (NASDAQ:IMRN) - ChartMill
Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference - Sahm
Immuron (NASDAQ: IMRN) boosts cash, pursues partners for IMM-124E and IMM-529 - Stock Titan
Immuron Reports HY26 Results and Strategic Reset - ChartMill
Immuron (NASDAQ: IMRN) gains A$1.12M non-dilutive R&D refund - Stock Titan
Immuron (NASDAQ: IMRN) shareholders back ratification of prior share issues - Stock Titan
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target - Newport Daily News
Immuron Reports Continued Sales Growth - Sahm
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - Benzinga
These stocks that are showing activity before the opening bell on Wednesday. - ChartMill
이뮤론 (IMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.84%
0.86%
자본화:
|
볼륨(24시간):